Arthritis Research & Therapy

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Fig. 1

ISSN: 1478-6362

Contact us

Submission enquiries: denizelucille.paraiso@springernature.com
General enquiries: info@biomedcentral.com